CCNE2 and acute myeloid leukemia: Salvatori et al. (2011) find that expression of miR-26a in acute myeloid leukemia cells inhibits cell cycle progression by down-regulating cyclin E2 expression, and they highlight miR-26a as an attractive therapeutic target in leukemia21.